ImmuneMed, Inc.
- Country
- ๐ฐ๐ทSouth Korea
- Ownership
- Holding
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.immunemed.co.kr
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06306339
- Locations
- ๐ณ๐ฑ
University Medical Center Urtrecht, Utrecht, GA, Netherlands
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Standard of care
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05808335
- Locations
- ๐ฐ๐ท
Chung-Ang University Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
๐ฐ๐ทSeoul National University Hospital, Seoul, Korea, Republic of
Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo (intravenous, single dose)Drug: hzVSF-v13 (intravenous, single dose)Drug: hzVSF-v13 (intravenous, multiple dose)Drug: hzVSF-v13 (subcutaneous, single dose)Drug: Placebo (intravenous, multiple dose)Drug: Placebo (subcutaneous, single dose)
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04817202
- Locations
- ๐ฆ๐บ
CMAX, Clinical Research Pty Ltd., Adelaide, South Australia, Australia
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04679350
- Locations
- ๐ฐ๐ท
Yeungnam University Medical Center, Daegu, Korea, Republic of
๐ฐ๐ทKeimyung University Dongsan Hospital, Daegu, Korea, Republic of
๐ฐ๐ทChungnam National University Hospital, Daejeon, Korea, Republic of
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04679415
- Locations
- ๐ฎ๐ฉ
Rumah Sakit Pusat Pertamina (include RSPP Extension Simprug), Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
๐ฎ๐ฉRumah Sakit Pasar Minggu, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
๐ฎ๐ฉRumah Sakit Umum Persahabatan, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04676971
- Locations
- ๐ฎ๐น
UOC Pneumologia, Bergamo, Italy
๐ฎ๐นDipartimento di Medicina Interna, Milano, Italy
๐ท๐บFederal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Russian Federation
Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03653208
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of